Posted by Michael Wonder on 24 Feb 2020
Japan Ministry of Health, Labor and Welfare approves Opdivo (nivolumab) for the treatment of patients with unresectable advanced or recurrent oesophageal cancer
21 February 2020 - First approval of Opdivo for treatment of advanced oesophageal cancer.
Bristol-Myers Squibb today announced Japan’s Ministry of Health, Labor and Welfare has approved Opdivo (nivolumab) for the treatment of patients with unresectable advanced or recurrent oesophageal cancer that has progressed following chemotherapy.
This approval is based on the Phase 3 ATTRACTION-3 trial, which evaluated Opdivo versus chemotherapy (docetaxel or paclitaxel) for the treatment of patients with unresectable advanced or recurrent oesophageal squamous cell carcinoma refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs.
